Martin Shkreli

Consider short-selling stocks in the Quantum Computing sector, which is viewed as a fraudulent bubble, with D-Wave (QBTS) and Arqit Quantum (BTQ) highlighted as top short candidates. The speaker is particularly bearish on Arqit Quantum (BTQ), calling it a "legit fraud" with a potential price target as low as three cents. On the bullish side, Sarepta Therapeutics (SRPT) is presented as a strong buying opportunity, with the speaker suggesting one should consider buying calls on the stock. Conversely, EVAXion (EVAX) is identified as a potential short opportunity due to skepticism surrounding its AI-based drug discovery model. Exercise caution with speculative 'Frontier Tech' stocks, as the broader market is seen as potentially overvalued and due for a significant sell-off.

Consider a long position in Spruce Biosciences (SPRB), with a potential entry point below $100 per share, as it is seen as a high-conviction play with a potential $1,000 long-term price target. For a turnaround opportunity, look at Sarepta Therapeutics (SRPT), which is considered a long-term buy for patient investors after it spends another quarter or two rebuilding market trust. Conversely, the quantum computing sector is presented as a high-conviction short opportunity, viewed as a speculative bubble detached from fundamentals. Specific companies to consider shorting include D-Wave (QBTS), Rigetti (RGTI), and BTQ, which are all expected to decline significantly over the long term. Investors should be cautious, as shorting these high-momentum stocks is risky and could lead to major short-term losses before the thesis plays out.

A high-conviction short-selling opportunity exists in the quantum computing sector, which one analyst dismisses as "fraud and hype" with no viable products. This bearish view targets speculative stocks like IonQ (IONQ), Rigetti Computing (RGTI), and D-Wave Quantum (QBTS), with a prediction they will eventually go to zero. In contrast, a strong bullish call was made on the biotech company Abivax (ABVX). Citing deep expertise in the drug industry, the analyst projects ABVX stock has the potential to reach a price target of $200. For investors seeking lower-risk exposure to the broader AI theme, established tech giants like Microsoft (MSFT) and Google (GOOGL) offer a more fundamentally sound alternative.

A major long-term opportunity exists in Advanced Micro Devices (AMD), as its new partnership with OpenAI provides a path to billions in new revenue and includes warrants tied to a $600 share price. For a more speculative bullish idea, consider Spruce Power (SPRB), a stock the analyst expressed direct interest in purchasing. On the bearish side, the entire quantum computing sector is seen as a high-conviction short opportunity, specifically targeting overvalued stocks like IONQ and RGTI. Another potential short is LAES (LAES), which was dismissed as a "fake company." These ideas align with a broader PetroAI theme, suggesting investors should watch capital flows into AI infrastructure, energy, and defense.

Consider a long position in Spruce Biosciences (SPRB), with a near-term price target of $200-$300 based on its promising rare disease drug and a proven business model. The entire Quantum Computing sector, including tickers like IonQ (IONQ) and BTQ Technologies (BTQ), is viewed as a strong avoid or short candidate due to a lack of viable technology. For an event-driven trade, consider shorting Capricor Therapeutics (CAPR) ahead of its upcoming HOPE-3 trial data, which is expected to fail. Sarepta Therapeutics (SRPT) presents another attractive long opportunity following recent positive three-year clinical data. Other biotech stocks mentioned favorably for long positions include Unicure (QURE) and Abivax (ABVX).

Consider shorting quantum computing stocks like IonQ (IONQ) and D-Wave (QBTS), which are viewed as high-conviction shorts with no viable business models. For a long-term bullish opportunity, Spruce Biosciences (SPRB) is seen as a deeply undervalued biotech company with a potential path to a $1 billion market cap. This significant upside for SPRB could translate to a potential share price of $700, though this is dependent on future FDA approvals. It is also advised to avoid or short companies with perceived flawed business models, such as Open Door (OPEN). Lastly, avoid betting against Tesla (TSLA), as shorting the stock is considered a highly risky proposition.

Consider a long position in Spruce Biosciences (SPRB), which is viewed as a high-conviction play with a potential price target of $500-$800 ahead of its planned FDA filing in Q1 2026. European biotech Abivax (ABVX) is also presented as a prime M&A target and a steady long-term investment, with a potential price of $200 per share. Conversely, investors should consider shorting or avoiding the quantum computing sector, specifically tickers like IONQ, QUBT, and RGTI, which are described as a speculative bubble. A contrarian opportunity may exist to short Advanced Micro Devices (AMD), as its recent OpenAI deal is viewed negatively with the stock potentially dropping below $200. For a shorter-term trade, Sarepta Therapeutics (SRPT) is a bullish idea that could reach $50 per share.

Consider researching pharmaceutical giant AbbVie (ABBV), as its drug pipeline, led by Skyrizi and Rinvoq, presents a potentially strong long-term investment. Biotechnology firm Sarepta Therapeutics (SRPT) received a direct bullish endorsement and is worth a closer look for those interested in the sector. For exposure to the popular GLP-1 weight-loss drug theme, investigate key players like Structure Therapeutics (GPCR) and Viking Therapeutics (VKTX). Highly speculative stocks like Quantum (QCI) are rallying in the current "risk-on" environment, but should be approached with extreme caution due to their high volatility. Finally, it may be wise to avoid stocks with recent poor performance and negative sentiment, such as Joby Aviation (JOBY) and Akero Therapeutics (AKRO).

A high-conviction bearish view is presented on the quantum computing sector, with specific short-selling opportunities identified in Rigetti (RGTI), IonQ (IONQ), and D-Wave (QBTS). The core thesis is that these companies are fundamentally overvalued and that the technology is not living up to its hype. Rigetti (RGTI) is singled out as a particularly attractive short, with the speaker calling it a "worthless company" at its current price. In contrast to the bearishness on quantum, a bullish sentiment was expressed towards memory chip manufacturers. As a result, investors seeking exposure to AI-related hardware may find Micron (MU) to be an exciting long-term opportunity.

A high-conviction, bullish opportunity has been identified in Sarepta Therapeutics (SRPT). The stock was highlighted at a price of $21 with a potential price target of $40 to $50. This represents a significant potential upside of approximately 90% to 138%. The speaker expressed confidence that the stock could reach this target "pretty easily." Investors may consider researching SRPT's drug pipeline and financial health to evaluate this opportunity.

Consider avoiding Anavex (AVXL) due to its lack of new data and the significant risk of a negative catalyst from an anticipated EMA rejection. Be wary of Capricor Therapeutics (CAPR), as the company's drug was recently rejected by the FDA, suggesting its stock price may be driven by hype rather than fundamentals. For a long-term AI investment, research Broadcom (AVGO) as a potential key player if the market shifts from GPUs to custom TPUs. This positions AVGO as a potential beneficiary in the next wave of AI hardware. Approach highly speculative themes like Quantum investing with extreme caution, as they represent a high-risk proposition unsuitable for most portfolios.

Consider a bearish stance on the quantum computing sector, as insiders believe it is overvalued and poised for a further decline, with Rigetti (RGTI) showing particular weakness. Conversely, Sarepta Therapeutics (SRPT) is viewed as a compelling long-term investment that is "too good to ignore." Similarly, uniQure (QURE) is highlighted as a strong performer with continued positive sentiment despite its recent price increase. For a shorter-term trade, European biotech firm Abivax (ABVX.PA) is expected to reach a price of 90 in the near future. The overall strategy suggests avoiding speculative tech sectors while selectively investing in high-conviction biotechnology names.

Consider a long position in Eli Lilly (LLY), which is showing exceptional growth driven by its blockbuster drugs Mounjaro and Zepbound. A strong bearish view is held on the Quantum Computing sector, which is seen as overhyped and facing a potential collapse as AI proves to be a more practical alternative. A high-conviction short position is active on Capper, with the expectation that the company's value will go to zero. Investors should avoid Ovid Therapeutics (OVID) ahead of its upcoming data release for OV329, which is viewed as a high-risk binary event with a low probability of success. This analysis suggests the technology behind quantum stocks is not living up to its promises, making the entire sector a potential short.

A strong bearish view is held on the Quantum Computing investment theme for the short-to-medium term. The sector is considered "hugely overhyped," with its near-term commercial viability being highly questionable. It is predicted that most commercial interest in the space will collapse within the next few years. Investors should therefore be extremely cautious about companies operating in the Quantum Computing sector. This serves as a warning about a potential bubble bursting in this technology theme.

The recent rally in highly shorted stocks is viewed as a speculative mania that is at or near its peak. The Quantum Computing sector is considered particularly overhyped, with recent gains in stocks like IonQ (Q) and Rigetti (RGTI) seen as disconnected from fundamentals. D-Wave (QBTS) is identified as a high-conviction short opportunity, based on the belief that the company has no customers and questionable value. Rigetti (RGTI) is also considered a compelling short, as its long-term potential is viewed with significant skepticism. Investors should be extremely cautious with these speculative names, as a sharp reversal is considered likely.

A strong bearish conviction is held against Anavex Life Sciences Corp. (AVXL), with the speaker confirming an active short position. This is a direct bet that the stock's price is likely to decrease. Separately, investors are advised to avoid Hims & Hers Health, Inc. (HIMS) entirely. The speaker sees no compelling reason to trade HIMS, suggesting investors should look for opportunities elsewhere. The analysis also highlights a key principle: avoid investing in sectors you don't understand, as demonstrated by the decision not to trade Oklo Inc. (OKLO).

Consider buying biotech stocks Sarepta Therapeutics (SRPT), due to positive reports on its drug Elevidys, and Replimune (REPL), which is seen as a continued buying opportunity. In the technology sector, video conferencing company Zoom (ZM) is highlighted as a "great buy." Conversely, a notable contrarian view suggests that mega-cap stock Amazon (AMZN) "might be a short." The host is actively shorting quantum computing stocks like IonQ (IONQ), Rigetti (RGTI), and D-Wave (QBTS), believing the sector is a speculative bubble. Finally, Anavex Life Sciences (AVXL) is strongly advised against, being labeled a "scam company."